| Company Name: |
Beijing Jin Ming Biotechnology Co., Ltd.
|
| Tel: |
010-60605840 15801484223; |
| Email: |
psaitong@jm-bio.com |
| Products Intro: |
Product Name:Pralnacasan
CAS:192755-52-5
Package:100mg;250mg;500mg Remarks: 试剂级
|
| Company Name: |
Nantong QuanYi Biotechnology Co., Ltd
|
| Tel: |
0513-66337626 18051384581 |
| Email: |
sales@chemhifuture.com |
| Products Intro: |
Product Name:Pralnacasan
CAS:192755-52-5
Purity:98%+ HPLC Package:10mg，500mg，1g，2g，5g，10g
|
| Company Name: |
RD International Technology Co., Limited
|
| Tel: |
18024082417 |
| Email: |
market@ubiochem.com |
| Products Intro: |
Product Name:Pralnacasan
CAS:192755-52-5
Purity:5mg;10mg;50mg;100mg;250mg;500mg;1g Package:5mg;10mg;50mg;100mg;250mg;500mg;1g
|
|
| | (3S,11S)-N-[(2R,3S)-2-ethoxy-5-oxo-oxolan-3-yl]-3-(isoquinoline-1-carbonylamino)-2,6-dioxo-1,7-diazabicyclo[5.4.0]undecane-11-carboxamide Basic information |
| Product Name: | (3S,11S)-N-[(2R,3S)-2-ethoxy-5-oxo-oxolan-3-yl]-3-(isoquinoline-1-carbonylamino)-2,6-dioxo-1,7-diazabicyclo[5.4.0]undecane-11-carboxamide | | Synonyms: | (3S,11S)-N-[(2R,3S)-2-ethoxy-5-oxo-oxolan-3-yl]-3-(isoquinoline-1-carbonylamino)-2,6-dioxo-1,7-diazabicyclo[5.4.0]undecane-11-carboxamide;(1S,9S)-N-[(2R,3S)-2-Ethoxy-5-oxotetrahydro-3-furanyl]-9-[(1-isoquinolinylcarbonyl)amino]-6,10-dioxooctahydro-6H-pyridazino[1,2-a][1,2]diazepine-1-carboxamide;HMR 3480;Pralnacasan;VX-740;6H-Pyridazino[1,2-a][1,2]diazepine-1-carboxamide, N-[(2R,3S)-2-ethoxytetrahydro-5-oxo-3-furanyl]octahydro-9-[(1-isoquinolinylcarbonyl)amino]-6,10-dioxo-, (1S,9S)- | | CAS: | 192755-52-5 | | MF: | C26H29N5O7 | | MW: | 523.54 | | EINECS: | | | Product Categories: | | | Mol File: | 192755-52-5.mol | ![(3S,11S)-N-[(2R,3S)-2-ethoxy-5-oxo-oxolan-3-yl]-3-(isoquinoline-1-carbonylamino)-2,6-dioxo-1,7-diazabicyclo[5.4.0]undecane-11-carboxamide Structure](CAS/GIF/192755-52-5.gif) |
| | (3S,11S)-N-[(2R,3S)-2-ethoxy-5-oxo-oxolan-3-yl]-3-(isoquinoline-1-carbonylamino)-2,6-dioxo-1,7-diazabicyclo[5.4.0]undecane-11-carboxamide Chemical Properties |
| density | 1.44±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | form | Solid | | pka | 10.80±0.40(Predicted) | | color | White to off-white |
| | (3S,11S)-N-[(2R,3S)-2-ethoxy-5-oxo-oxolan-3-yl]-3-(isoquinoline-1-carbonylamino)-2,6-dioxo-1,7-diazabicyclo[5.4.0]undecane-11-carboxamide Usage And Synthesis |
| Uses | Treatment of rheumatoid arthritis;
(interleukin-1β converting enzyme (also known as caspase-
1) inhibitor). | | Brand name | Aventis; Vertex. | | in vivo | Pralnacasan (0 -50 mg/kg; oral gavage; twice a day; for 6 weeks; female Balb/c mice) treatment reduces joint damage. Pralnacasan treatment does not appear to affect the weight of the animals[1]. | Animal Model: | Female Balb/c mice induced with collagenase[1] | | Dosage: | 0 mg/kg, 12.5 mg/kg, 25 mg/kg and 50 mg/kg | | Administration: | Oral gavage; twice a day; for 6 weeks | | Result: | Significantly ameliorated the histopathological damage of the medial knee joint compartments.
|
| | IC 50 | Interleukin-1β converting enzyme: 1.4 nM (Ki) |
| | (3S,11S)-N-[(2R,3S)-2-ethoxy-5-oxo-oxolan-3-yl]-3-(isoquinoline-1-carbonylamino)-2,6-dioxo-1,7-diazabicyclo[5.4.0]undecane-11-carboxamide Preparation Products And Raw materials |
|